Advanced search
1 file | 109.42 KB

Early effects of human papillomavirus vaccination in Belgium

Author
Organization
Abstract
Human papillomavirus (HPV) vaccination has been reimbursed in Belgium since 2007 for girls (12-15 years), extended to girls up to 18 years in 2008. This study assesses the trend of HPV 16/18 infections in women less than 25 years of age participating in opportunistic cervical cancer screening. A significant reduction in the prevalence of HPV 16 [relative risk (RR)=0.61, 95% confidence interval=0.39-0.95] and a nonsignificant reduction in HPV 18 (RR=0.65, 95% confidence interval=0.29-1.48) was found in the youngest group (15-19 years). The prevalences in the older age group did not change significantly. These findings show the early effects of HPV vaccination and confirm the effectiveness of immunization in a real-life setting.
Keywords
surveillance, HPV vaccine impact, HPV vaccine, cervical cancer, adolescents, CROSS-PROTECTIVE EFFICACY, GRADE CERVICAL LESIONS, METAANALYSIS, PREVENTION, INFECTION, CANCER

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 109.42 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Merckx, Mireille, Davy Vanden Broeck, Ina Benoy, Christophe Depuydt, Steven Weyers, and Marc Arbyn. 2015. “Early Effects of Human Papillomavirus Vaccination in Belgium.” European Journal of Cancer Prevention 24 (4): 340–342.
APA
Merckx, Mireille, Vanden Broeck, D., Benoy, I., Depuydt, C., Weyers, S., & Arbyn, M. (2015). Early effects of human papillomavirus vaccination in Belgium. EUROPEAN JOURNAL OF CANCER PREVENTION, 24(4), 340–342.
Vancouver
1.
Merckx M, Vanden Broeck D, Benoy I, Depuydt C, Weyers S, Arbyn M. Early effects of human papillomavirus vaccination in Belgium. EUROPEAN JOURNAL OF CANCER PREVENTION. 2015;24(4):340–2.
MLA
Merckx, Mireille, Davy Vanden Broeck, Ina Benoy, et al. “Early Effects of Human Papillomavirus Vaccination in Belgium.” EUROPEAN JOURNAL OF CANCER PREVENTION 24.4 (2015): 340–342. Print.
@article{5765612,
  abstract     = {Human papillomavirus (HPV) vaccination has been reimbursed in Belgium since 2007 for girls (12-15 years), extended to girls up to 18 years in 2008. This study assesses the trend of HPV 16/18 infections in women less than 25 years of age participating in opportunistic cervical cancer screening. A significant reduction in the prevalence of HPV 16 [relative risk (RR)=0.61, 95\% confidence interval=0.39-0.95] and a nonsignificant reduction in HPV 18 (RR=0.65, 95\% confidence interval=0.29-1.48) was found in the youngest group (15-19 years). The prevalences in the older age group did not change significantly. These findings show the early effects of HPV vaccination and confirm the effectiveness of immunization in a real-life setting.},
  author       = {Merckx, Mireille and Vanden Broeck, Davy and Benoy, Ina and Depuydt, Christophe and Weyers, Steven and Arbyn, Marc},
  issn         = {0959-8278},
  journal      = {EUROPEAN JOURNAL OF CANCER PREVENTION},
  keyword      = {surveillance,HPV vaccine impact,HPV vaccine,cervical cancer,adolescents,CROSS-PROTECTIVE EFFICACY,GRADE CERVICAL LESIONS,METAANALYSIS,PREVENTION,INFECTION,CANCER},
  language     = {eng},
  number       = {4},
  pages        = {340--342},
  title        = {Early effects of human papillomavirus vaccination in Belgium},
  url          = {http://dx.doi.org/10.1097/CEJ.0000000000000067},
  volume       = {24},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: